AI Medic (CEO Eun-bo Shim) announced that it has signed a supply contract with Gangnam Severance Hospital (Director Sung-wook Koo) Health Checkup Center (hereinafter Gangnam Severance Health Checkup) for the cardiovascular diagnostic solution HeartMedi+ and will begin providing full-scale service support starting in June.
HeartmediPlus is a non-invasive precision diagnosis solution that simulates fractional flow reserve (FFR) by visualizing the coronary artery in three dimensions using cardiac CT images. Unlike the past when invasive procedures were required to evaluate the degree of coronary artery stenosis in patients, blood flow analysis is possible with just a CT scan, and quantitative risk can be measured without a procedure, enabling early detection and preemptive treatment strategy establishment.
With the signing of this supply contract, AI Medic will supply Heartmedi Plus to Gangnam Severance Health Checkup, making it the first domestic health checkup center to introduce artificial intelligence-based cardiovascular risk assessment technology.
An official from AI Medical stated, “This is the first case in Korea where AI-based CT-FFR technology has been applied to the general health checkup area,” and “Since precise cardiac diagnosis is now possible even during regular health checkups for the general public, we have established a new medical ecosystem that can detect high-risk groups for cardiovascular disease early and diagnose them non-invasively.”
He then revealed his future plans, saying, “We will actively expand partnerships with major hospitals across the country so that more people can benefit from cutting-edge medical technology.”
Gangnam Severance Health Checkup Director Young-Hoon Yoon (Professor of Gastroenterology) said, “In order to achieve the goal of becoming a ‘new medical culture innovation leader,’ we are actively introducing various AI-based screening programs, including Heartmedi Plus. We will create a health screening environment that enhances accuracy and safety while increasing the convenience of examinees.”
Previously, Heartmediplus received a Class 3 medical device product approval (Approval No. 23-92) from the Ministry of Food and Drug Safety in 2023, and was designated as an innovative medical technology in accordance with the Ministry of Health and Welfare Notice No. 2023-202 in the same year, completing temporary registration with health insurance. It is currently being applied to outpatient treatment at major domestic hospitals, including Gangnam Severance Hospital.
- See more related articles
You must be logged in to post a comment.